当前位置:首页 > 文献互助 > 互助详情

Real-World Safety Profile of Xanomeline-Trospium (Cobenfy), the First Muscarinic Agonist Antipsychotic: A Disproportionality Analysis of the FDA Adverse Event …复制

用户dO6Bp_vxHIqQ 27分钟前 11 10 待确认 帖子自动结束时间: 2026-07-29 11:36:21

1. 请及时下载文件确认是否正确, 系统将在 2026-07-31 12:02:13 删除文件

2. 如若文件有误请驳回应助文件, 求助状态即回到求助中

3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI:复制

文献链接:复制

其他信息:

H Farquhar
Available at SSRN 6611902
papers.ssrn.com
Background: Xanomeline-trospium (Cobenfy), the first antipsychotic with a non-dopaminergic mechanism approved in over 30 years, received FDA approval for schizophrenia in September 2024. Its muscarinic M1/M4 agonist mechanism may produce a different adverse event profile compared with conventional antipsychotics, but post-marketing data have not been comprehensively evaluated with active-comparator analyses. We aimed to characterise the safety profile of xanomeline-trospium using …

互助时间线

2026-07-24 12:02:13 [上传文件]

jodie0105上传了文件(pdf 278.82 KB), 求助状态变成 待确认

2026-07-24 11:36:21 [发起求助]

最新发布的求助